All In Biotech

Drug Trial Radar · NCT05857384

Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugs

A Randomised Four-Period Cross-Over Phase I Study to Assess Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugs in Healthy Volunteers

Last checked: Nov 20, 2026Latest source record: Jan 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 125 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

125

Actual

Start

Sep 8, 2023

Primary completion

Jul 31, 2024

Study completion Jul 31, 2024

Sponsor

Lead sponsor
Incannex Healthcare LtdIndustry
Sponsor type
Industry
First posted
May 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this randomised four-period cross-over Phase I study is to assess bioavailability, bioequivalence and tolerability of IHL-42X compared to the reference drugs in healthy volunteers. Volunteers will be enrolled and randomised to one of four treatment groups. Each group is to receive all four treatments in a twenty eight day cross-over study, with each treatment period running for seven days. The four treatment groups are described below; A = dronabinol 5 mg, fasted; B = acetazolamide 250 mg, fasted; C = IHL-42X (5 mg dronabinol, 250 mg acetazolamide), fasted; D = IHL-42X (5 mg dronabinol, 250 mg acetazolamide), fed. Each treatment group will enrol at least 29 participants each, for a total of at least 116 participants. Bioavailability and bioequivalence will assess and compare all four of the seven day treatments.

Conditions

  • Obstructive Sleep Apnea

Interventions

  • IHL42XDrug

    IHL-42X consists of acetazolamide and dronabinol.

  • Acetazolamide 250 MGDrug

    A solid tablet containing 250 mg acetazolamide

  • Dronabinol 2.5 MGDrug

    A soft gelatin capsules containing 2.5mg dronabinol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Bioavailability of IHL-42XTime frame: 28 days
  2. Bioequivalence of IHL-42XTime frame: 28 days
  3. Effect of food on IHL-42X - maximum observed drug concentrationTime frame: 7 days
  4. Effect of food on IHL-42X - time of the maximum drug concentrationTime frame: 7 days
  5. Effect of food on IHL-42X - area under the drug concentration time curve from time zero to time of last measurable concentrationTime frame: 7 days
  6. Effect of food on IHL-42X - area under the drug concentration time curve from time zero to infinityTime frame: 7 days
  7. Effect of food on IHL-42X - area under the drug concentration time curve from time zero to 12 hoursTime frame: 7 days
  8. Effect of food on IHL-42X - area under the drug concentration time curve from time zero to 24 hoursTime frame: 7 days
  9. Effect of food on IHL-42X - the elimination half-lifeTime frame: 7 days
  10. Effect of food on IHL-42X - terminal elimination rate constantTime frame: 7 days
  11. Effect of food on IHL-42X - apparent total body clearanceTime frame: 7 days
  12. Effect of food on IHL-42X - apparent volume of distributionTime frame: 7 days

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • CMAX

    Adelaide, South Australia, Australia

  • Nucleus Network Pty Ltd

    Geelong, Victoria, Australia

  • Nucleus Network Pty Ltd [Commercial Road]

    Melbourne, Victoria, Australia

  • Nucleus Network Pty Ltd

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.